Kala Bio Q2 Results: Loss per share narrows 75.11% YoY to $(21.32)
Kala Bio reported a quarterly loss of $(21.32) per share in Q2, a 75.11% improvement from a loss of $(85.64) per share in the same period last year. Sales for the quarter were $0.00, unchanged from the prior year period.
*this image is generated using AI for illustrative purposes only.
Kala Bio reported a quarterly loss of $(21.32) per share in Q2, reflecting a 75.11% improvement over the loss of $(85.64) per share recorded in the same period last year. Sales for the quarter stood at $0.00, unchanged from the same period last year.
Q2 financial performance
The following table summarises Kala Bio's key financial metrics for the quarter compared to the same period last year.
| Metric: | Q2 (Current) | Q2 (Prior Year) | Change |
|---|---|---|---|
| Loss per share: | $(21.32) | $(85.64) | +75.11% improvement |
| Sales: | $0.00 | $0.00 | No change |
What specific operational cost-cutting measures or strategic shifts contributed to the 75% improvement in loss per share despite zero revenue?
When does Kala Bio expect to generate its first commercial sales, and what are the key milestones required to reach that revenue inflection point?
How does the current cash runway compare to the reduced burn rate, and will the company need to raise additional capital before achieving profitability?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
